Last year Sunesis completed the VALOR trial, the first clinical study to make use of the groundbreaking promising zone design. The promising zone design implements an unblinded sample re-estimation after an interim look, but only if conditional power during the interim look falls within a designated promising zone. Although the VALOR trial did not confirm the efficacy of the new therapeutic, it provided the drug with the best possible chance to prove its efficacy.
The video below shows Jennifer Smith, the Executive Director of Biometrics at Sunesis, and Cytel President Cyrus Mehta, discuss the Statistical and Operational Challenges of the VALOR trial. Smith and Mehta spoke as a part of the Cytel and ASA sponsored event Statistical Innovations in Clinical Development.
Related Items of Interest
How to Plan Interim Looks in Adaptive Clinical Trials: 3 Strategies
How to Shorten a Cardiovascular Outcome Trial By Two Years
FDA-Industry Session on Cardiovascular Outcome Trials: Mehta on EXAMINE Trial’s Promising Zone Design
Adaptive Clinical Trial Strategies for the Limited Early Phase Budget
